« Back
Home /
Citarinostat

Citarinostat

Item no.	HY-15994-1mg
Manufacturer	MedChem Express
CASRN	1316215-12-9
Amount	1 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.66
Citations	[1]Huang P, et al. Selective HDAC inhibition by ACY-241 enhances the activity of NSC 125973 in solid tumor models. Oncotarget. 2017 Jan 10;8(2):2694-2707.
Smiles	O=C(C1=CN=C(N(C2=CC=CC=C2Cl)C3=CC=CC=C3)N=C1)NCCCCCCC(NO)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	ACY241
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	HDAC
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	467.95
Product Description	Citarinostat (ACY241) is a second generation potent, orally active and high-selective HDAC6 inhibitor with an IC50 of 2.6 nM (IC50s of 35 nM, 45 nM, 46 nM and 137 nM for HDAC1, HDAC2, HDAC3 and HDAC8, respectively). Citarinostat has anticancer effects[1].
Manufacturer - Research Area	Cancer
Solubility	DMSO: ≥ 30 mg/mL
Manufacturer - Pathway	Cell Cycle/DNA Damage; Epigenetics
Isoform	HDAC1; HDAC2; HDAC3; HDAC6; HDAC7; HDAC8
Clinical information	Phase 1

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15994-1mg-safety-datasheet.pdf